Below are the research areas that are the focus of the EASL Consortium for Regenerative Hepatology. The benefits of achieving these outcomes are wide-reaching. Not only will they result in direct clinical benefits for liver disease patients but by default will provide benefits to the broader research community.
Create a 5% bio-engineered liver mass in order to develop “implantable liver tissue” for the treatment of inherited hepatic metabolic disorders.
Create bioengineered bile ducts to be used in liver transplant and congenital biliary diseases.
Create a 30% bio-engineered liver mass for transplantation in patients with acute or acute-on-chronic liver failure.